Why Wait? Initiating Contingency Management in Traumatically Injured Patients During Hospitalization
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Contingency management.
- Who it may be relevant to
- Registry conditions: Contingency Management, Methamphetamine Use Disorder. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This clinical trial is to implement contingency management (CM) as an intervention tool to address methamphetamine use and will be initiated during inpatient acute hospitalization in trauma injured patients. The goals are: * Gather effectiveness data on a CM program for participants in Hawaii who use methamphetamine during hospitalization and following discharge due to trauma injury * To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program. * To assess the rate of leaving against medical advice (AMA) and treatment completion in acute hospital setting in participants. * To assess the optimal timing of CM initiation for traumatically injured hospitalized patients by comparing patient outcomes (i.e. duration of CM participation and rates of CM program completion and providing negative urine samples) to NCT06532370 where CM was initiated after discharge from the hospital. For total of 12 weeks, participants will: * Be visited on Mondays/Thursdays or Tuesdays/Fridays by the research team to complete urine analysis during the hospitalization * Visit a follow up clinic up to 2 times per week on Mondays/Thursdays or Tuesdays/Fridays to complete urinalysis following discharge from the hospital * Complete Treatment Effectiveness Assessments at 6 and 12 weeks * Engage in qualitative interview at the end of the CM program
Interventions
- Behavioral Contingency management
If the urine sample is methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately 50% of the slips offer written praises (i.e. "great job!"). The other 50% of slips are the divided between low value (i.e. food gift cards, bus passes), medium value (i.e. prepaid cellphone, clothing gift cards), and a few large value rewards (i.e. electronic
Primary outcome measures
- Treatment Effectiveness Assessments (TEA) at 6- and 12-weeks post-enrollment [Time frame: From enrollment to 6 and 12 weeks]
Secondary outcome measures (1)
- Conduct qualitative interviews with participants post-program [Time frame: At the end of the treatment at 12 weeks]
Eligibility criteria
Inclusion criteria
- Admitted trauma patients
- Age greater than 18 years old
- Urine drug screen positive for methamphetamines during the current hospitalization
- Report at least weekly methamphetamine use
- First methamphetamine use greater than 6 months prior to injury
- Report at least 4 Diagnostic and Statistical Manual of Mental Disorders 5th Edition, Amphetamine-Type Substance Use Disorder symptoms (at least moderate disease)
- Glasgow Coma Scale ≥13 upon arrival to the emergency department
- Ability to understand and participate in study procedures
- Ability to communicate in English
- Expected discharge date within 45 days on the day of screening / recruitment
Exclusion criteria
- Active psychosis (reporting auditory or visual hallucinations)
- Under ongoing cardiorespiratory monitoring
- Evidence of moderate or severe traumatic brain injury
- Patients who are known to be pregnant
- Prisoners
- Individuals incarcerated at the time of their hospitalization
- Individuals lacking capacity to provide, or are otherwise unable or unwilling to provide written informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 1 center
- The Queen's Medical Center — Honolulu
Identifiers
NCT: NCT06931197 · RA-2025-012